Computational tools have the potential to enable rapid material-free developability assessments of large molecule candidates. With wide spanning roles across early discovery through to downstream development activities, when utilized effectively, computational techniques can shorten timelines and enhance the cost-effectiveness of biologic drug development.
Building upon the framework and success of the past two iterations of the event, the 3rd CDD for Biologics Summit remains the solely dedicated to exploring the power of in silico tools to de-risk your biologics drug development.
Focused principally on design and developability of monoclonal antibodies, case studies will reveal the applications of these methods to other biotherapeutic modalities, from early drug discovery through to late preclinical development.
Through sharing of novel insights from our industry-leading faculty, topics to be discussed include: improving predictability of target ID and validation, understanding protein/protein interactions, enhancing rational candidate selection, and optimizing developability characteristics.
Join us to:
- Benchmark against the leaders in the field to understand how they have effectively integrated in-house and commercially available computational tools into their biologics development workflow
- Use robust in silico strategies to streamline the discovery of biologics, significantly reducing the investment required for early experimental techniques
- Investigate how computational tools can optimize the manufacturability and physical properties of biotherapeutics
- Examine real-world case studies, detailing how the use of MD simulations, in silico affinity maturation, computational structural modelling and a host of other techniques have contributed significant value to lead candidates
- Gain invaluable insights into how informatics, modelling and simulation can overcome key challenges encountered the development of biologics